FOR IMMEDIATE RELEASE
San Carlos, California, United States of America (Free-Press-Release.com) May 9, 2013 -- Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, today announced that results from its Psoriasis PhysioPD collaboration and results from its PhysioMap projects will be presented at the 2013 American Conference on Pharmacometrics in Fort Lauderdale Florida, May 12-15. Dr. Rebecca Baillie will present two posters. The first poster, entitled "Physiological model to investigate and prioritize targets for psoriasis", will describe the development and use of a custom-designed Psoriasis PhysioMap, which provided information and methodology that enabled key decisions in early development target prioritization. This project informed the selection and prioritization of drug development targets. The second poster, entitled "Using Qualitative Modeling in Drug Development", will describe how qualitative mechanistic modeling, or "PhysioMaps", have been used throughout the drug discovery and development process, and it will present an analysis of the results of these types of projects.
"We are pleased to share our insightful work in qualitative PhysioMap modeling and the results of our collaboration in inflammatory skin disease. Rigorous qualitative modeling provides clear benefits and guidance in a short time frame in many situations, and is a precursor to the quantitative PhysioPD modeling that can elucidate complex biologic systems and modern therapies against chronic diseases," said Dr. Christina Friedrich, Principal and Chief Engineer, PhysioPD, at Rosa.
About Rosa
Rosa informs our customer's most critical decisions – from preclinical through clinical development – with the creation and use of mathematical models that simulate disease physiology, drug action, patient variability, and trial outcomes. To address the full spectrum of related issues, Rosa offers two customized approaches: classic pharmacokinetic/ pharmacodynamic (PK/PD) models and Rosa's innovative PhysioPD? models. With these approaches, Rosa's clients collaborate in model creation and testing, retain the final model, and acquire the ability to use it and understand its implications for their drug development programs. Rosa's staff have unparalleled professional experience in using drug-disease modeling and simulation (M&S) to accelerate drug development and have completed hundreds of engagements with dozens of clients in multiple therapeutic areas. The Rosa team is unique in their breadth and depth of disease area experience, which includes metabolic and cardiovascular diseases, oncology, gastro-intestinal disease, inflammatory diseases, immune dysfunction (including rheumatoid arthritis), pain, skin conditions, respiratory disorders, and antibacterials/antivirals.
